App-Quantinova.ai

Spontaneous polymerisation by forming intermolecular disulfide bridges involving this cysteine residue helps to identify haemoglobin Porto Alegre on delayed cation‐exchange high‐performance liquid chromatography (HPLC)

J. King - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Cysteine Hydrochloride

Response to intravenous iron in the iron‐restricted population that are intolerant or refractory to oral iron

A. Korb - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Ferric carboxymaltose

Gray Platelet Syndrome: more than an inherited bleeding disorder

J. Collins - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Autoimmune Thyroid Disease

N/A

Diagnostic high‐throughput sequencing of 2,390 patients with bleeding, thrombotic and platelet disorders

K. Downes - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Real world effectiveness of thrombopoietin receptor agonists (TRAs) in the management of immune thrombocytopenia (ITP) in the UK: results from a post hoc analysis of the TRAIT study

N. Cooper - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Immune thrombocytopenia

Mycophenolate mofetil

Platelet contribution to clot formation and fibrinolysis

R. Aungraheeta - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Tranexamic acid

A Survey of UK Myeloma treating centres on thrombosis risk assessment and thromboprophylaxis practice in patients with Multiple Myeloma

R. Oliver - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Multiple Myeloma

apixaban

The top 10 research priorities in bleeding disorders: a James Lind Alliance Priority Setting Partnership

S. Shapiro - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

Warfarin is well absorbed from gastric mucosa alone in patients with extensive bowel resection: A case report of a patient with ultrashort bowel syndrome following portal and superior mesenteric vein thrombosis and antiphospholipid syndrome

M. Khakwani - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Antiphospholipid syndrome

Warfarin

Argatroban sensitivity of different APTT reagents at King's College Hospital

F. Pereira - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Argatroban

A Conservative Approach to Screening for Occult Malignancy after Unprovoked DVT: The King's College Hospital DVT Clinic Experience

J.R. Czuprynska - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Use of antithrombin concentrate in acquired antithrombin deficiency in acutely unwell children receiving unfractionated heparin – a single centre experience

D. Jayakody Arachchillage - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Thrombocytopenia

Heparin

Incidences of thrombosis, major bleeding and 30‐day mortality in patients receiving veno‐venous extracorporeal membrane oxygenation and value of laboratory parameters at presentation in predicting outcomes

D. Jayakody Arachchillage - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

Lack of agreement between different anti‐Xa assays to measure low molecular weight heparin (LMWH); results of a UK NEQAS Blood Coagulation study

I. Jennings - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Enoxaparin

S. Westbury - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Macrothrombocytopenia

N/A

Single centre audit of testing F8 genetics and identifying the p.Tyr365Cys mutation in mild haemophilia A: implications for patient care and resources

R. Chengal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary embolism

Tranexamic acid

The detection and management of inhibitors in severe haemophilia patients — the experience of a large UK paediatric tertiary haemophilia centre

C. Horgan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hemophilia

Recombinant Factor VIII

Superficial Vein Thrombosis: Deeper Than You Think ‐ A Single Centre Experience

D. Gosrani - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Angiology

Superficial Vein Thrombosis

N/A

Coagulation status of critically ill patients with liver disease assessed using a novel thrombin generation analyser

G.B. Morrow - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Thrombomodulin alfa

Double Double Trouble – Two Cases of Acquired Immune Thrombocytopenia Complicating Congenital Haemophilia

C.S. Booth - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Immune thrombocytopenia

Dexamethasone

Filters

45280 Abstracts